Disease · EFO_0008586
Non-ST Elevation Myocardial Infarction
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. Non-ST Elevation Myocardial Infarction. Diseases, record EFO_0008586. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0008586
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- NON-STEMI, NSTEMI, Non-ST Elevation Myocardial Infarction by ECG Finding, Non-ST Elevation Myocardial Infarction by EKG Finding
- Open Targets
Drugs14
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| PRASUGREL | CHEMBL1201772 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| TICAGRELOR | CHEMBL398435 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| CLOPIDOGREL | CHEMBL1771 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| INCLISIRAN | CHEMBL3990033 | Oligonucleotide | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ANPOCOGIN | CHEMBL4298082 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ATULIFLAPON | CHEMBL4802195 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| BQ-123 | CHEMBL314691 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| EVOLOCUMAB | CHEMBL2364655 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| INCLACUMAB | CHEMBL2109488 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SELATOGREL | CHEMBL4297589 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 14
See all 14 drugsTargets9
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| P2RY12 | P2Y purinoceptor 12 | 4 | Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 negative allosteric modulator | Phase 3 | https://conductscience.org/library/genes/64805 | Drugs and targets |
| PCSK9 | PCSK9 mRNA | 2 | PCSK9 mRNA RNAi inhibitor; Subtilisin/kexin type 9 inhibitor | Phase 3 | https://conductscience.org/library/genes/255738 | Drugs and targets |
| EDNRA | Endothelin-1 receptor | 1 | Endothelin receptor ET-A antagonist | Phase 2 | https://conductscience.org/library/genes/1909 | Drugs and targets |
| IL6R | Interleukin-6 receptor subunit alpha | 1 | Interleukin-6 receptor alpha subunit inhibitor | Phase 2 | https://conductscience.org/library/genes/3570 | Drugs and targets |
| ITGA2B | Integrin alpha-IIb/beta-3 | 1 | Integrin alpha-IIb/beta-3 inhibitor | Unknown | https://conductscience.org/library/genes/3674 | Drugs and targets |
| ITGAV | Integrin alpha-V/beta-3 | 1 | Integrin alpha-V/beta-3 inhibitor | Unknown | https://conductscience.org/library/genes/3685 | Drugs and targets |
| ITGB3 | Integrin alpha-IIb/beta-3 | 1 | Integrin alpha-IIb/beta-3 inhibitor; Integrin alpha-V/beta-3 inhibitor | Unknown | https://conductscience.org/library/genes/3690 | Drugs and targets |
| MTOR | Serine/threonine-protein kinase mTOR | 1 | Serine/threonine-protein kinase mTOR inhibitor | Unknown | https://conductscience.org/library/genes/2475 | Drugs and targets |
| SELP | P-selectin | 1 | P-selectin antagonist | Phase 2 | https://conductscience.org/library/genes/6403 | Drugs and targets |
Trials15
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00699998 | A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects | Phase 3 | 9,326 | 2013-05-07 | Acute Coronary Syndrome | CLOPIDOGREL, PRASUGREL | Its record names the disease | ClinicalTrials.gov |
| NCT01015287 | A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction | Phase 3 | 4,033 | 2014-02-28 | Acute Coronary Syndromes | PRASUGREL | Its record names the disease | ClinicalTrials.gov |
| NCT03822377 | Ticagrelor Administered as Standard Tablet or Orodispersible Formulation | Phase 3 | 130 | 2021-09-08 | ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI | TICAGRELOR | Its record names the disease | ClinicalTrials.gov |
| NCT03317002 | AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD). | Phase 2 | 129 | 2021-06-30 | Coronary Artery Disease | ATULIFLAPON | Its record names the disease | ClinicalTrials.gov |
| NCT03515304 | Evolocumab in Acute Coronary Syndrome | Phase 2 | 60 | 2025-11-24 | Acute Coronary Syndrome | EVOLOCUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03487445 | A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack | Phase 2 | 48 | 2021-08-25 | Acute Myocardial Infarction | SELATOGREL | Its record names the disease | ClinicalTrials.gov |
| NCT00586820 | Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI | Phase 2 | 23 | 2014-07-04 | Myocardial Reperfusion Injury | BQ-123 | Its record names the disease | ClinicalTrials.gov |
| NCT01327183 | A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention | Phase 2 | 532 | Myocardial Infarction | INCLACUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT00116012 | Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32 | Phase 2 | 300 | Coronary Disease | ANPOCOGIN | Its record names the disease | ClinicalTrials.gov | |
| NCT07102628 | Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | Phase 3 | 300 | Acute Coronary Syndrome | INCLISIRAN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 15
See all 15 trialsComparisons in its trials14
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Prasugrel vs Clopidogrel: serious adverse events | 1,573 of 4,623 | 1,594 of 4,617 | 9,240 | NCT00699998 | Trial comparisons |
| Non Pre-treatment vs Pre-treatment: serious adverse events | 167 of 1,996 | 206 of 2,037 | 4,033 | NCT01015287 | Trial comparisons |
| Experimental Arm vs Control Arm: Percent of Patients With Insufficient Antiaggregation | 51 of 65 | 53 of 65 | 130 | NCT03822377 | Trial comparisons |
| Experimental Arm vs Control Arm: Incidence of Adverse Events Occurring During Hospital Stay | 14 of 65 | 15 of 65 | 130 | NCT03822377 | Trial comparisons |
| Ticagrelor Orodispersible Tablets vs Ticagrelor Standard Tablets: Number of Participants With Residual Platelet Reactivity at Various Timepoints | 42 of 65 | 9 of 65 | 130 | NCT03822377 | Trial comparisons |
| Ticagrelor Orodispersible Tablets vs Ticagrelor Standard Tablets: Number of Participants With Morphine-ticagrelor Interaction | 6 of 65 | 4 of 65 | 130 | NCT03822377 | Trial comparisons |
| Ticagrelor Orodispersible Tablets vs Ticagrelor Standard Tablets: Number of Participants With Clinically Relevant Bleeding Events | 0 of 65 | 4 of 65 | 130 | NCT03822377 | Trial comparisons |
| Ticagrelor Orodispersible Tablets vs Ticagrelor Standard Tablets: deaths from any cause | 0 of 65 | 0 of 65 | 130 | NCT03822377 | Trial comparisons |
| Ticagrelor Orodispersible Tablets vs Ticagrelor Standard Tablets: serious adverse events | 1 of 65 | 0 of 65 | 130 | NCT03822377 | Trial comparisons |
| Evolocumab vs Placebo: deaths from any cause | 0 of 30 | 0 of 30 | 60 | NCT03515304 | Trial comparisons |
1 to 10 of 14
See all 14 comparisons in its trialsPapers from its trials46
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 40780143 | DERIVED | 1 | PubMed |
| 39073758 | DERIVED | 1 | PubMed |
| 35842004 | DERIVED | 1 | PubMed |
| 35314069 | DERIVED | 1 | PubMed |
| 35224730 | DERIVED | 1 | PubMed |
| 34266583 | DERIVED | 1 | PubMed |
| 32862694 | DERIVED | 1 | PubMed |
| 32439008 | DERIVED | 1 | PubMed |
| 30935633 | DERIVED | 1 | PubMed |
| 30819358 | DERIVED | 1 | PubMed |
1 to 10 of 46
See all 46 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0008586
GET https://conductscience.org/api/diseases/v1/EFO_0008586/papers?page=2